SPRY
ARSCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
+
Peers tracked
10
U.S. public peers
Grade Position
In line
vs peer average
SPRY vs peer average
50/100
SPRY vs. peer average (C vs. C)
Grade spread
A 1 · B 4 · C 1 · D 2 · F 2
Graded peers loaded
Coverage
10 graded
100% of tracked
Peer overview
PHAT is the first available peer comparator.
Phathom is a better commercialization-stage biotech comp than large-cap pharma because investors can compare launch execution, payer/access friction, and cash-burn tolerance, though the GI indication and market structure differ materially from neffy.
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
SPRY
ARS
PHAT
Phathom
Grade
C
B
Momentum
5
29
Value
41
41
Sentiment
93
95
Setup Bias
Net —
-
Market Cap
-
-
Posture
Mixed
Constructive
Grade position vs PHAT
SPRY / PHAT
Grade Position
In line
SPRY vs. peer average (C vs. C)
50/100
Momentum
5
PHATValue
41
SPRYSentiment
93
PHATRotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs SPRY
PHAT is the first peer returned for this comparison set.